Effect of dipeptidyl peptidase-4 inhibitors on glycated hemoglobin levels relies on dietary sodium intake.
Dietary sodium intake
Dipeptidyl peptidase 4 inhibitor
Glycated hemoglobin
Type 2 diabetes mellitus
Journal
Diabetes & metabolic syndrome
ISSN: 1878-0334
Titre abrégé: Diabetes Metab Syndr
Pays: Netherlands
ID NLM: 101462250
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
06
03
2023
revised:
04
06
2023
accepted:
06
06
2023
medline:
14
7
2023
pubmed:
22
6
2023
entrez:
21
6
2023
Statut:
ppublish
Résumé
Sodium load increases endogenous glucagon-like peptide-1 (GLP-1) levels in humans. Therefore, patients with an increased amount of dietary sodium intake are supposed to have higher endogenous GLP-1 levels compared to those with less dietary sodium intake. Therefore, it can be hypothesized that patients with type 2 diabetes mellitus (T2DM) with more dietary sodium intake show better dipeptidyl peptidase-4 inhibitor (DPP-4i) effect on glycemic control because of the expected higher GLP-1 level. Thus, we performed a single-center cohort study to explore this idea. Medical records of patients with T2DM prescribed DPP-4i in the last 11 years were investigated. Dietary sodium intake was measured before the DPP-4i prescription with Tanaka's formula using casual spot urine samples. The effect of DPP-4i on glycemic control was estimated by the subtraction of glycated hemoglobin (HbA1c) before DPP-4i initiation from HbA1c 1 year after DPP-4i administration. We analyzed 50 patients. DPP-4i improved HbA1c by -0.41% ± 0.66%. The effect of DPP-4i on glycemic control was significantly negatively correlated with the dietary sodium intake (r = -0.400). Thus, the more dietary sodium intake, the better the glycemic control by DPP-4i. Thus, patients can expect better plasma glucose control by DPP-4is if patients are taking increased dietary sodium intake.
Identifiants
pubmed: 37343509
pii: S1871-4021(23)00102-9
doi: 10.1016/j.dsx.2023.102806
pii:
doi:
Substances chimiques
Dipeptidyl-Peptidase IV Inhibitors
0
Glycated Hemoglobin
0
Hypoglycemic Agents
0
Glucagon-Like Peptide 1
89750-14-1
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
EC 3.4.14.-
Sodium, Dietary
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102806Informations de copyright
Copyright © 2023 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.